MECOM and acute myeloid leukemia: Different studies have proposed that, alongside adverse TP53 Mut AML, other selected adverse-risk genotypes like AML with complex karyotype and inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1) should be stratified as very adverse risk due to their significantly worse CR rates, EFS, and OS [5,6,26].